TIE2 (Y1108F)

TEK · Variant type: point · HGVS: p.Y1108F

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Ponatinib	96.0%	4.0%	78.23
2	Crizotinib	84.5%	15.5%	91.39
3	Cabozantinib	75.4%	24.6%	92.73
4	Axitinib	68.9%	31.1%	93.23
5	Brigatinib	63.3%	36.7%	82.96
6	Nintedanib	61.9%	38.1%	90.23
7	Repotrectinib	58.8%	41.2%	84.21
8	Ripretinib	57.3%	42.7%	92.95
9	Dabrafenib	49.5%	50.5%	94.74
10	Tivozanib	40.1%	59.9%	92.42
11	Nilotinib	38.9%	61.1%	96.49
12	Vandetanib	32.3%	67.7%	95.74
13	Fostamatinib	28.2%	71.8%	96.74
14	Infigratinib	26.7%	73.3%	98.24
15	Lenvatinib	26.2%	73.8%	97.74
16	Bosutinib	22.5%	77.5%	87.22
17	Erdafitinib	22.3%	77.7%	95.71
18	Ibrutinib	19.5%	80.5%	94.74
19	Neratinib	18.6%	81.4%	93.18
20	Vemurafenib	15.0%	85.0%	96.49
21	Dasatinib	13.3%	86.7%	87.97
22	Rabusertib	11.5%	88.5%	98.74
23	Pemigatinib	11.0%	89.0%	98.23
24	Regorafenib	10.5%	89.5%	95.99
25	Tenalisib	9.0%	91.0%	97.98

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Ponatinib	96.0%	—	—
Crizotinib	84.5%	—	—
Cabozantinib	75.4%	—	—
Axitinib	68.9%	—	—
Brigatinib	63.3%	—	—
Nintedanib	61.9%	—	—
Repotrectinib	58.8%	—	—
Ripretinib	57.3%	—	—
Dabrafenib	49.5%	—	—
Tivozanib	40.1%	—	—
Nilotinib	38.9%	—	—
Vandetanib	32.3%	—	—
Fostamatinib	28.2%	—	—
Infigratinib	26.7%	—	—
Lenvatinib	26.2%	—	—
Bosutinib	22.5%	—	—
Erdafitinib	22.3%	—	—
Ibrutinib	19.5%	—	—
Neratinib	18.6%	—	—
Vemurafenib	15.0%	—	—
Dasatinib	13.3%	—	—
Rabusertib	11.5%	—	—
Pemigatinib	11.0%	—	—
Regorafenib	10.5%	—	—
Tenalisib	9.0%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 18.1ms